Results 161 to 170 of about 1,055,250 (236)

Cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults - results from the ActiFE study. [PDF]

Eur J Clin Pharmacol
Lorenz L, Berres J, Denkinger MD, Rothenbacher D, Braig S, Dallmeier D, Just KS.   +6 more
europepmc   +1 more source

Anticholinergic burden in community-dwelling older adults: prevalence, associated factors, and agreement between measurement scales. [PDF]

Front Pharmacol
Rodríguez-Salas FB, Merchán-Cruz MA, Ocaña-Riola R, Díez-de-Baldeón-Chicón PM, Lara JP, Blanco-Reina E.   +5 more
europepmc   +1 more source

Japanese Anticholinergic Risk Scale and Domain-Specific Functional Outcomes in Older Poststroke Patients. [PDF]

Geriatr Gerontol Int
Matsumoto A, Yoshimura Y.
europepmc   +1 more source

Anticholinergic drugs and risk of dementia: case-control study.

BMJ, 2019
europepmc   +1 more source

Monitoring and addressing anticholinergic-induced ocular adverse effects associated with psychotropic medication. [PDF]

Ment Health Clin
Gilbert J, Vorachek J, Pelnick S.
europepmc   +1 more source

Anticholinergic Burden in Individuals with Down Syndrome: An Examination of Risk and Clinical Implications. [PDF]

J Pers Med
Villani ER, Liperoti R, Franza L, Secciani FM, Di Paola A, Onder G, Carfì A.   +6 more
europepmc   +1 more source

The Association Between Anticholinergic Burden and Treatment-Related Complications in Older Adults with Cancer. [PDF]

Drugs Aging
Brokaar EJ, Trompet S, Portielje JEA, Visser LE, Mooijaart SP, Uit den Boogaard A, Baltussen JC, van Holstein Y, van den Bos F.   +8 more
europepmc   +1 more source